Indication

Target/marker/pathway

Summary

Licensing status

Publication and contact information

Cancer

Acute myeloid leukemia (AML);
B cell acute lymphoblastic lymphoma (B-ALL)

Cluster of differentiation 1C (CD1C)

Cell culture and mouse studies suggest methyl-lysophosphatidic acids presented by CD1C could be useful for stimulating immune response against AML and B-ALL. In vitro, synthetic analogs of methyl-lysophosphatidic acids bound to CD1C on AML and B-ALL cells and resulted in a stronger T cell response than vehicle. In a mouse xenograft model of AML, T cells primed with methyl-lysophosphatidic acids decreased tumor growth and improved survival compared with unprimed T cells. Next steps could include developing autologous transplantation protocols to prime therapeutic T cells to react against tumor-derived lipids such as methyl-lysophosphatidic acids.

SciBX 7(29); doi:10.1038/scibx.2014.853
Published online July 31, 2014

Patent and licensing status undisclosed

Lepore, M. et al. J. Exp. Med.; published online June 16, 2014;
doi:10.1084/jem.20140410
Contact: Gennaro De Libero, University of Basel, Basel, Switzerland
e-mail:
gennaro.delibero@unibas.ch

Contact: Lucia Mori, same affiliation as above
e-mail:
lucia.mori@unibas.ch

Contact: Giulia Casorati, San Raffaele Scientific Institute, Milan, Italy
e-mail:
casorati.giulia@hsr.it

Contact: Paolo Dellabona, same affiliation as above
e-mail:
dellabona.paolo@hsr.it